GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Piotroski F-Score

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Piotroski F-Score : 0 (As of Jun. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pathfinder Cell Therapy has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Pathfinder Cell Therapy's Piotroski F-Score or its related term are showing as below:


Pathfinder Cell Therapy Piotroski F-Score Historical Data

The historical data trend for Pathfinder Cell Therapy's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy Piotroski F-Score Chart

Pathfinder Cell Therapy Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 4.00 3.00 3.00 3.00

Pathfinder Cell Therapy Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 3.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep15) TTM:Last Year (Sep14) TTM:
Net Income was -0.293 + -0.276 + -0.222 + -0.289 = $-1.08 Mil.
Cash Flow from Operations was -0.127 + -0.176 + -0.098 + -0.178 = $-0.58 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Sep14)
to the end of this year (Sep15) was
(0.07 + 0.106 + 0.086 + 0.049 + 0.039) / 5 = $0.07 Mil.
Total Assets at the begining of this year (Sep14) was $0.07 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.01 Mil.
Total Current Liabilities was $6.77 Mil.
Net Income was -0.462 + -0.485 + -0.332 + -0.284 = $-1.56 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was -0.013 + 0 + 0 + 0 = $-0.01 Mil.
Average Total Assets from the begining of last year (Sep13)
to the end of last year (Sep14) was
(0.208 + 0.155 + 0.142 + 0.073 + 0.07) / 5 = $0.1296 Mil.
Total Assets at the begining of last year (Sep13) was $0.21 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.04 Mil.
Total Current Liabilities was $5.72 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pathfinder Cell Therapy's current Net Income (TTM) was -1.08. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pathfinder Cell Therapy's current Cash Flow from Operations (TTM) was -0.58. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep14)
=-1.08/0.07
=-15.42857143

ROA (Last Year)=Net Income/Total Assets (Sep13)
=-1.563/0.208
=-7.51442308

Pathfinder Cell Therapy's return on assets of this year was -15.42857143. Pathfinder Cell Therapy's return on assets of last year was -7.51442308. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Pathfinder Cell Therapy's current Net Income (TTM) was -1.08. Pathfinder Cell Therapy's current Cash Flow from Operations (TTM) was -0.58. ==> -0.58 > -1.08 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep15)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep14 to Sep15
=0/0.07
=0

Gearing (Last Year: Sep14)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep13 to Sep14
=0/0.1296
=0

Pathfinder Cell Therapy's gearing of this year was 0. Pathfinder Cell Therapy's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep15)=Total Current Assets/Total Current Liabilities
=0.009/6.769
=0.00132959

Current Ratio (Last Year: Sep14)=Total Current Assets/Total Current Liabilities
=0.037/5.72
=0.00646853

Pathfinder Cell Therapy's current ratio of this year was 0.00132959. Pathfinder Cell Therapy's current ratio of last year was 0.00646853. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Pathfinder Cell Therapy's number of shares in issue this year was 667.161. Pathfinder Cell Therapy's number of shares in issue last year was 667.161. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-0.013/0
=

Pathfinder Cell Therapy's gross margin of this year was . Pathfinder Cell Therapy's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep14)
=0/0.07
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep13)
=0/0.208
=0

Pathfinder Cell Therapy's asset turnover of this year was 0. Pathfinder Cell Therapy's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pathfinder Cell Therapy has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Pathfinder Cell Therapy  (OTCPK:PFND) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Pathfinder Cell Therapy Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Traded in Other Exchanges
N/A
Address
12 Bow Street, Cambridge, MA, USA, 02138
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Executives
John J Alam director 130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines